News
GeoVax Labs
GOVX · NASDAQ
$0.2271−$0.0004 (−0.18%)TodayMarket closed ·
Prev close $0.2275
Latest news
- News
'White House Adds Pandemic Response Staff as Ebola Cases Rise' - Bloomberg News
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAkanksha Bakshi
GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- NewsAvi Kapoor
Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
US Stocks Edge Lower; Advance Auto Parts Posts Upbeat Earnings
- NewsAvi Kapoor
Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Dow Gains Over 200 Points; Conagra Shares Fall After Q2 Results
- Press releasePRNewswire
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
- News
'1 Person Dies Of The Plague In Northern Arizona' - FOX 2 Detroit
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
World Health Organization Says MPOX Remains A Public Health Emergency Of International Concern
- NewsAvi Kapoor
Crude Oil Moves Lower; Citigroup Posts Upbeat Results
- NewsAvi Kapoor
Nasdaq Surges 100 Points; Bank of America Earnings Top Views
- NewsRishabh Mishra
US Stock Futures Waver After Two-Day Rally: Trump's Tariff Moves Could End A 3-Year 'Rolling Recession,' Says Expert
- News
What's Next: Geovax Labs's Earnings Preview
- News
"New Case Of Mpox Detected In The UK After 'Concerning' Surge In Cases In Uganda" - Manchester Evening News
- Press releaseGlobe Newswire
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
- Press releaseGlobe Newswire
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
- NewsAvi Kapoor
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday
- News
Earnings Preview: Geovax Labs
- News
Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times
- NewsChris Katje
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
- News
'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA
- News
'U.S. Prepares For Possible Arrival Of More Severe Strain Of Mpox; There Have Been Nearly 25,000 Cases Of The Clade 1 Version Of Mpox In Africa So Far This Year" - NBC
- News
'First Delivery Of Mpox Vaccine Doses From The Commission Arrive Today In The Democratic Republic Of Congo' - European Commission
- NewsChris Katje
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?
- Press releaseGlobe Newswire
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
- Press releaseGlobe Newswire
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
- NewsChris Katje
WHO Declares Mpox Public Health Emergency: 'Coordinated International Response Essential' To Halt Outbreak
- Press releaseGlobe Newswire
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.